The Cancer Paradigm of Severe Angioproliferative Pulmonary Hypertension

[1]  R. Speich,et al.  Increased Regulatory and Decreased CD8+ Cytotoxic T Cells in the Blood of Patients with Idiopathic Pulmonary Arterial Hypertension , 2007, Respiration.

[2]  W. Jiang,et al.  Bone morphogenetic proteins and their receptor signaling in prostate cancer. , 2007, Histology and histopathology.

[3]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[4]  Frank Rose,et al.  Metastasis: the seed and soil theory gains identity , 2007, Cancer and Metastasis Reviews.

[5]  S. Erzurum,et al.  Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[6]  S. Archer,et al.  The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted , 2007, Proceedings of the National Academy of Sciences.

[7]  N. Voelkel,et al.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. , 2007, American journal of respiratory and critical care medicine.

[8]  M. Katoh.  Networking of WNT, FGF, Notch, BMP, and Hedgehog Signaling Pathways during Carcinogenesis , 2007, Stem Cell Reviews.

[9]  K. Stenmark,et al.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[10]  M. Humbert,et al.  Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension , 2007, European Respiratory Journal.

[11]  J. Prchal,et al.  Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. , 2007, Blood.

[12]  W. Kummer,et al.  Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice , 2007, Respiratory research.

[13]  D. Celermajer,et al.  Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. , 2007, Journal of the American College of Cardiology.

[14]  Kazuto Nakamura,et al.  Diverse Contribution of Bone Marrow-Derived Cells to Vascular Remodeling Associated With Pulmonary Arterial Hypertension and Arterial Neointimal Formation , 2007, Circulation.

[15]  Raed A Dweik,et al.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[16]  N. Voelkel,et al.  Endothelial Biomedicine: The Central Role of Endothelial Cells in Severe Angioproliferative Pulmonary Hypertension , 2007 .

[17]  P. Insel,et al.  Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[18]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[19]  H. Tan,et al.  How valid are animal models to evaluate treatments for pulmonary hypertension? , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[20]  Larry Norton,et al.  Is cancer a disease of self-seeding? , 2006, Nature Medicine.

[21]  D. Scadden,et al.  The stem-cell niche as an entity of action , 2006, Nature.

[22]  D. McKean,et al.  Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[23]  Minjin Lee,et al.  Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. , 2006, Pathology, research and practice.

[24]  Buchynska Lg,et al.  Expression of the cell cycle regulators p53, p21(WAF1/CIP1) and p16(INK4a) in human endometrial adenocarcinoma. , 2006 .

[25]  L. Pardo,et al.  Potassium channels as tumour markers , 2006, FEBS letters.

[26]  M. Colombo,et al.  Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. , 2006, Cancer research.

[27]  N. Voelkel,et al.  Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. , 2006, Chest.

[28]  M. Humbert,et al.  BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension , 2006, Human mutation.

[29]  M. Mcgoon,et al.  Diagnostic Dilemmas: Diastolic Heart Failure Causing Pulmonary Hypertension and Pulmonary Hypertension Causing Diastolic Dysfunction , 2006 .

[30]  S. Groshong,et al.  Pulmonary hypertension: cellular and molecular mechanisms. , 2005, Chest.

[31]  D. Badesch,et al.  Autoimmunity and pulmonary hypertension: a perspective , 2005, European Respiratory Journal.

[32]  D. McDonald,et al.  Imaging of angiogenesis in inflamed airways and tumors: newly formed blood vessels are not alike and may be wildly abnormal: Parker B. Francis lecture. , 2005, Chest.

[33]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[34]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[35]  S. Rafii,et al.  Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9–mediated progenitor cell mobilization , 2005, The Journal of experimental medicine.

[36]  Raymond C. Boston,et al.  Dynamic Imaging of Allogeneic Mesenchymal Stem Cells Trafficking to Myocardial Infarction , 2005, Circulation.

[37]  P. Jones,et al.  Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension , 2005, Circulation.

[38]  N. Voelkel,et al.  Initial apoptosis is followed by increased proliferation of apoptosis‐resistant endothelial cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[40]  D. Ivy,et al.  Development of Occlusive Neointimal Lesions in Distal Pulmonary Arteries of Endothelin B Receptor—Deficient Rats: A New Model of Severe Pulmonary Arterial Hypertension , 2005, Circulation.

[41]  S. Archer,et al.  Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.

[42]  R. Trembath,et al.  BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[43]  A. Zaiman,et al.  Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[44]  J. Dyck,et al.  Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.

[45]  L. Pardo.  Voltage-gated potassium channels in cell proliferation. , 2004, Physiology.

[46]  J. Yuan,et al.  Overexpression of human KCNA5 increases IK V and enhances apoptosis. , 2004, American journal of physiology. Cell physiology.

[47]  Troy Stevens,et al.  Open Access Activated Leukocyte Cell Adhesion Molecule in Breast Cancer: Prognostic Indicator , 2022 .

[48]  M. Wick,et al.  Peroxisome Proliferator-Activated Receptor Gamma (PPAR&ggr;) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth , 2003, Circulation research.

[49]  Heinz Baumann,et al.  Signal transducer and activator of transcription proteins in leukemias. , 2003, Blood.

[50]  J. Yuan,et al.  Cytochrome c activates K+ channels before inducing apoptosis. , 2002, American journal of physiology. Cell physiology.

[51]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[52]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[53]  N. Voelkel,et al.  The pathobiology of pulmonary hypertension. Endothelium. , 2001, Clinics in chest medicine.

[54]  R. Trembath,et al.  Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins , 2001, Circulation.

[55]  A. Caplan,et al.  The Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion , 2001, Cells Tissues Organs.

[56]  E. Manseau,et al.  Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. , 2001, The American journal of pathology.

[57]  N. Voelkel,et al.  Microsatellite Instability of Endothelial Cell Growth and Apoptosis Genes Within Plexiform Lesions in Primary Pulmonary Hypertension , 2001, Circulation research.

[58]  M. Kizaki,et al.  Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. , 2000, Blood.

[59]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[60]  K J O'Byrne,et al.  The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. , 2000, European journal of cancer.

[61]  R. L. Williams,et al.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. , 1999, The American journal of pathology.

[62]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[63]  J. Orens,et al.  Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. , 1998, Circulation.

[64]  N. Voelkel,et al.  Primary pulmonary hypertension between inflammation and cancer. , 1998, Chest.

[65]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[66]  Wei Zhang,et al.  Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. , 1997, The American journal of pathology.

[67]  M. Pepper,et al.  Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. , 1997, Cytokine & growth factor reviews.

[68]  S. Archer,et al.  Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[69]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[70]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[71]  L. Reid,et al.  Hypoxic remodeling of the rat pulmonary arterial microcirculation assessed by microdissection. , 1991, Journal of applied physiology.

[72]  Wagenvoort Ca.  Vasoconstrictive primary pulmonary hypertension and pulmonary veno-occlusive disease. , 1972 .

[73]  D. Dresdale,et al.  Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. , 1954, Bulletin of the New York Academy of Medicine.